Marchel A
Kliniki Neurochirurgii Instytutu Chirurgii AM, Warszawie.
Neurol Neurochir Pol. 1992 Jul-Aug;26(4):502-10.
The value of the antifibrinolytic treatment was assessed in two groups od patients treated after subarachnoid haemorrhage from ruptured aneurysm. One group of 449 patients received EACA before the operation, and 308 were not given EACA. The effectiveness of this treatment was analysed considering the frequency of recurrent haemorrhages, site of aneurysm and sequelae of recurrent haemorrhage as well as ischaemic complications of subarachnoid haemorrhage. The frequency of recurrent haemorrhages was significantly lower in the group not treated with EACA, and the frequency of ischaemic complications of subarachnoid haemorrhage was significantly higher in those treated with EACA.
在两组因破裂动脉瘤导致蛛网膜下腔出血后接受治疗的患者中评估了抗纤维蛋白溶解治疗的价值。一组449例患者在手术前接受了6-氨基己酸(EACA)治疗,308例未接受EACA治疗。从复发性出血的频率、动脉瘤部位、复发性出血的后遗症以及蛛网膜下腔出血的缺血性并发症等方面分析了该治疗的有效性。未接受EACA治疗组的复发性出血频率显著较低,而接受EACA治疗组的蛛网膜下腔出血缺血性并发症频率显著较高。